Streetbeat News

ETNB

89bio, Inc.

https://www.89bio.com

Industry

Biotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Open

7.82

Mkt cap

904M

Volume

1.1M

High

7.89

P/E Ratio

-2.60

52-wk high

16.63

Low

7.44

Div yield

N/A

52-wk low

7.00

89bio presented new analyses at The Liver Meeting® 2024, highlighting the potential benefits of pegozafermin in treating MASH patients. The analyses suggest pegozafermin's anti-fibrotic effects and the utility of non-invasive tests correlating with histological endpoints.

Portfolio Pulse from

November 15, 2024 | 1:15 pm

89bio, Inc. has announced the upsized pricing of its $125 million public offering of common stock and pre-funded warrants. The offering includes 11,455,882 shares at $8.50 each and pre-funded warrants for 3,250,000 shares at $8.499 each. The offering is expected to close on November 14, 2024.

Portfolio Pulse from

November 13, 2024 | 5:15 am

89bio, Inc. has announced a proposed underwritten public offering of $100 million in common stock and pre-funded warrants, with an option for underwriters to purchase an additional $15 million. The offering is subject to market conditions.

Portfolio Pulse from

November 12, 2024 | 9:15 pm

89bio, Inc. (NASDAQ:ETNB) will present new analyses from its Phase 2b ENLIVEN trial on pegozafermin for treating metabolic dysfunction-associated steatohepatitis (MASH) at the AASLD Liver Meeting 2024.